The Dry AMD market report also offers comprehensive insights into the Dry AMD market size, share, Dry AMD epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Dry AMD market size growth forward.
Some of the key highlights from the Dry AMD Market Insights Report:
In February 2025, Luxa Biotechnology announced that the FDA had granted Regenerative Medicine Advanced Therapy (RMAT) designation to its RPESC-RPE-4W transplantation for the treatment of dry age-related macular degeneration (dry AMD). Luxa is advancing this innovative adult retinal pigment epithelial stem cell therapy to benefit patients with dry AMD.
On November 5, 2024, the U.S. FDA approved LumiThera’s Valeda Light Delivery System for commercial use in the treatment of dry age-related macular degeneration (AMD).
In 2023, the U.S. market for Dry Age-related Macular Degeneration was valued at approximately USD 800 million, with projections indicating continued growth throughout the forecast period (2024–2034).
In 2023, in the 7MM the total Dry AMD market size was ~ USD 1,300 million.
Dry AMD has the potential to progress to geographic atrophy, a stage characterized by irreversible vision loss caused by the depletion of crucial retinal components such as retinal pigment epithelium (RPE), photoreceptors, and choriocapillaris in the macula.
Although this condition is not uncommon in clinical practice, it can go undetected until the atrophy involves the fovea and affects central vision. Patients do not consult an ophthalmologist until they notice visual impairment due to foveal involvement.
Multimodal imaging is advised for evaluating geographic atrophy presence and progression. Optical coherence tomography (OCT) stands out among these modalities as it proves valuable in identifying progression biomarkers in patients with intermediate AMD and in assessing the macula while quantifying geographic atrophy lesions.
The majority of pipeline candidates for dry AMD target geographic atrophy, an advanced stage, rather than focusing on the early and intermediate stages.
Detecting early biomarkers signaling the risk of progression from intermediate AMD to vision-threatening late stages is crucial for personalized management and timely intervention.
Current interventions for dry AMD, such as nutritional supplements (e.g., AREDS formulation) and lifestyle modifications, aim to slow disease progression and manage symptoms. However, their efficacy varies among individuals, and they do not address the underlying pathology comprehensively.
Several therapeutic modalities are currently in clinical trials for treating dry AMD, including complement pathway inhibitors, visual cycle modulators, reducing toxic byproducts, antioxidative therapy, neuroprotective agents, laser therapy, surgery, gene therapy, stem cell therapy, and miscellaneous treatments.
SYFOVRE (pegcetacoplan) by Apellis and IZERVAY (avacincaptad pegol) by Astellas both are approved to treat geographic atrophy, also known as late-stage dry AMD. They are administered through eye injection. Now, with these two medications being the only options for geographic atrophy, a rivalry has emerged between the two companies as they compete for dominance in treating this condition. Clinicians face a challenge in comparing the efficacy data of IZERVAY and SYFOVRE as the studies for these treatments have distinct designs, making direct head-to-head comparisons difficult. However, post-marketing safety concerns are a major threat to both SYFOVRE and IZERVAY.
The potential therapies that can mark a significant change in the upcoming forecast period include AVD-104, Tinlarebant (LBS-008), Gildeuretinol (ALK-001), Elamipretide, ANX007, Danicopan (ALXN2040), IONIS-FB-LRx (RG6299), JNJ-1887, CPCB-RPE1, OpRegen, and others.
AVD-104 is striving to be the third therapy approved by the FDA for treating geographic atrophy secondary to AMD.
Elamipretide is a mitochondrial stabilizing agent, the only class to have demonstrated a potential to improve low luminance visual acuity (LLVA) in dry AMD.
Data from both CPCB-RPE1 and OpRegen provides a very believable likelihood that RPE cells provide an effective means for treating dry AMD with geographic atrophy.
Several key pharmaceutical companies, including Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics (CellCure Neurosciences), Roche, Cognition Therapeutics, Stealth BioTherapeutics, Evergreen Therapeutics, Annexon Biosciences, NGM Biopharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Ionis Pharmaceuticals, Novartis, Regenerative Patch Technologies, and others, are developing novel products to improve the Dry AMD treatment outlook.
Dry AMD therapies are IZERVAY (avacincaptad pegol), SYFOVRE (pegcetacoplan), Iptacopan (LNP023), ALK-001, and others.
As per DelveInsight analysis, the Dry AMD market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Dry AMD Market Landscape
Dry AMD Overview
By 1965, the terminology associated with AMD had become widely accepted, with the disease categorized into three clinical stages: early, intermediate, and advanced AMD. The hallmark of early AMD is the presence of drusen (measuring between >63 and ≤125 µm in diameter), which affects the patient’s ability to adjust to changes in lighting conditions. However, significant central vision loss primarily occurs in the intermediate and advanced stages, with advanced AMD including both geographic atrophy and neovascular AMD.
Geographic atrophy is characterized by the gradual degeneration of the macular retinal pigment epithelium (RPE), photoreceptor layer, and choroidal capillaries, leading to progressive vision impairment over time. Diagnosis relies on comprehensive eye examinations, while treatment strategies focus on slowing disease progression and maximizing the use of remaining vision.
Despite these efforts, there is currently no cure for advanced dry AMD, highlighting the urgent need for continued research to develop effective therapies for this vision-threatening condition.
Do you know the treatment paradigms for different countries? Download our Dry AMD Market Sample Report
Dry AMD Epidemiology Insights
In 2023, the total number of prevalent AMD cases across the 7MM was approximately 68,347,900.
Among these regions, the United States had the highest number of dry AMD cases, with around 20,970,000 cases reported that year. This number is projected to rise over the forecast period.
Several studies have indicated a decline in the prevalence of late-stage AMD in the U.S. when comparing data from the 2000s to earlier decades.
In the same year, geographic atrophy accounted for approximately 955,900 cases across the EU4 countries and the UK.
Dry AMD Epidemiology Segmentation
DelveInsight’s Dry AMD market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Dry AMD historical patient pools and forecasted Dry AMD patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Dry AMD Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
Dry AMD Prevalence
Age-Specific Dry AMD Prevalence
Gender-Specific Dry AMD Prevalence
Diagnosed and Treatable Cases of Dry AMD
Visit for more @ Dry AMD Epidemiological Insights
Dry AMD Market Outlook
Geographic atrophy (GA), the advanced stage of dry AMD, has become a key area of research. Current studies primarily focus on therapies that target complement inhibitors of C3 and C5, which play a crucial role in triggering inflammation and cell death in the eye. Extensive research, including studies led by the National Eye Institute and renowned scientists worldwide, suggests that an overactive complement system is a major contributor to the development of dry AMD and its progression to GA.
A deeper understanding of the pathophysiology of GA caused by dry AMD can benefit patients, optometrists, and ophthalmologists by improving diagnosis and patient identification. This, in turn, could help reduce the disease burden and preserve visual function for a longer period.
The research and development landscape has shifted its focus from intermediate AMD to dry AMD, as demonstrated by Stealth Biotherapeutics’ decision to prioritize dry AMD treatments. Elamipretide, a mitochondria-targeting antioxidant, has advanced to Phase II trials for dry AMD after showing promising results in Phase I trials for intermediate AMD.
Immune response-targeting agents represent the most advanced area of clinical research for GA and have become the first and only drug class to receive FDA approval. The approvals of IZERVAY (avacincaptad pegol) and SYFOVRE (pegcetacoplan) mark a significant milestone, as both treatments have been proven to slow GA progression and reduce vision loss. These developments are reshaping clinical practice, research priorities, investment strategies, and healthcare planning. While these therapies offer hope to patients with late-stage dry AMD, they are only the first steps toward expanding treatment options for GA.
Several therapies are currently being investigated to slow GA progression and preserve macular function in dry AMD patients. Clinical trials focusing on disease prevention and progression control include promising candidates such as ALK-001, Elamipretide, Risuteganib, EG-301, ANX 007, IONIS-FB-LRx, NGM 621, and JNJ-1887 (AAVCAGsCD59), among others.
Dry AMD Marketed Therapies
IZERVAY (avacincaptad pegol): Astellas Pharma/Iveric Bio
SYFOVRE (pegcetacoplan): Apellis Pharmaceuticals
Dry AMD Emerging Therapies
Iptacopan (LNP023): Novartis
ALK-001: Alkeus Pharmaceuticals
Dry AMD Key Companies
Alkeus Pharmaceuticals
Belite Bio
Aviceda Therapeutics
Johnson & Johnson Innovative Medicine
Allegro Ophthalmics
Lineage Cell Therapeutics (CellCure Neurosciences)
Roche
Cognition Therapeutics
Stealth BioTherapeutics
Evergreen Therapeutics
Annexon Biosciences
NGM Biopharmaceuticals
AstraZeneca
Alexion Pharmaceuticals
Ionis Pharmaceuticals
Novartis
Regenerative Patch Technologies
For more information, visit Dry AMD Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Dry AMD Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Dry AMD, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Dry AMD epidemiology in the 7MM
Dry AMD marketed and emerging therapies
Dry AMD companies
Dry AMD market drivers and barriers
Table of Contents:
1 Dry AMD Market Key Comprehensive Insights
2 Dry AMD Market Report Introduction
3 Competitive Intelligence Analysis for Dry AMD
4 Dry AMD Market Analysis Overview at a Glance
5 Executive Summary of Dry AMD
6 Dry AMD Epidemiology and Market Methodology
7 Dry AMD Epidemiology and Patient Population
8 Dry AMD Patient Journey
9 Dry AMD Treatment Algorithm, Dry AMD Current Treatment, and Medical Practices
10 Key Endpoints in Dry AMD Clinical Trials
11 Dry AMD Marketed Therapies
12 Dry AMD Emerging Therapies
13 Dry AMD: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Dry AMD
16 Dry AMD Market Key Opinion Leaders Reviews
18 Dry AMD Market Drivers
19 Dry AMD Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Dry AMD Epidemiology 2034
DelveInsight’s “Dry AMD – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Dry AMD epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Dry AMD Pipeline 2024
“Dry AMD Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Dry AMD market. A detailed picture of the Dry AMD pipeline landscape is provided, which includes the disease overview and Dry AMD treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
